nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—ALB—Vandetanib—thyroid cancer	0.181	0.233	CbGbCtD
Norethindrone—CYP3A7—Sorafenib—thyroid cancer	0.117	0.151	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.117	0.151	CbGbCtD
Norethindrone—CYP3A5—Sorafenib—thyroid cancer	0.0879	0.113	CbGbCtD
Norethindrone—CYP2C19—Sorafenib—thyroid cancer	0.0709	0.0911	CbGbCtD
Norethindrone—ABCB1—Sorafenib—thyroid cancer	0.0572	0.0735	CbGbCtD
Norethindrone—CYP3A4—Vandetanib—thyroid cancer	0.0569	0.073	CbGbCtD
Norethindrone—ABCB1—Doxorubicin—thyroid cancer	0.0347	0.0446	CbGbCtD
Norethindrone—CYP3A4—Sorafenib—thyroid cancer	0.0343	0.044	CbGbCtD
Norethindrone—CYP3A4—Doxorubicin—thyroid cancer	0.0208	0.0267	CbGbCtD
Norethindrone—Embolism arterial—Epirubicin—thyroid cancer	0.0149	0.0674	CcSEcCtD
Norethindrone—Embolism arterial—Doxorubicin—thyroid cancer	0.0138	0.0624	CcSEcCtD
Norethindrone—Carcinoma—Sorafenib—thyroid cancer	0.00964	0.0435	CcSEcCtD
Norethindrone—Cerebral haemorrhage—Sorafenib—thyroid cancer	0.00526	0.0237	CcSEcCtD
Norethindrone—Acne—Vandetanib—thyroid cancer	0.00513	0.0231	CcSEcCtD
Norethindrone—Gastrointestinal symptom NOS—Sorafenib—thyroid cancer	0.00495	0.0223	CcSEcCtD
Norethindrone—Embolism—Sorafenib—thyroid cancer	0.00454	0.0205	CcSEcCtD
Norethindrone—Neoplasm malignant—Sorafenib—thyroid cancer	0.00341	0.0154	CcSEcCtD
Norethindrone—Erythema nodosum—Epirubicin—thyroid cancer	0.00249	0.0112	CcSEcCtD
Norethindrone—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00247	0.0112	CcSEcCtD
Norethindrone—Depression—Vandetanib—thyroid cancer	0.00241	0.0109	CcSEcCtD
Norethindrone—Renal failure—Vandetanib—thyroid cancer	0.00237	0.0107	CcSEcCtD
Norethindrone—Erythema nodosum—Doxorubicin—thyroid cancer	0.0023	0.0104	CcSEcCtD
Norethindrone—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00228	0.0103	CcSEcCtD
Norethindrone—Haemoglobin—Vandetanib—thyroid cancer	0.00218	0.00983	CcSEcCtD
Norethindrone—Haemorrhage—Vandetanib—thyroid cancer	0.00217	0.00978	CcSEcCtD
Norethindrone—Pain in extremity—Sorafenib—thyroid cancer	0.00211	0.00954	CcSEcCtD
Norethindrone—Erythema multiforme—Vandetanib—thyroid cancer	0.00205	0.00925	CcSEcCtD
Norethindrone—Mood swings—Sorafenib—thyroid cancer	0.002	0.00904	CcSEcCtD
Norethindrone—Blindness—Epirubicin—thyroid cancer	0.00194	0.00877	CcSEcCtD
Norethindrone—Alopecia—Vandetanib—thyroid cancer	0.00192	0.00864	CcSEcCtD
Norethindrone—Breast disorder—Sorafenib—thyroid cancer	0.00191	0.00862	CcSEcCtD
Norethindrone—Mental disorder—Vandetanib—thyroid cancer	0.0019	0.00857	CcSEcCtD
Norethindrone—Blindness—Doxorubicin—thyroid cancer	0.0018	0.00812	CcSEcCtD
Norethindrone—Optic neuritis—Epirubicin—thyroid cancer	0.00175	0.00789	CcSEcCtD
Norethindrone—Embolism—Epirubicin—thyroid cancer	0.00168	0.00756	CcSEcCtD
Norethindrone—Convulsion—Vandetanib—thyroid cancer	0.00164	0.00738	CcSEcCtD
Norethindrone—Optic neuritis—Doxorubicin—thyroid cancer	0.00162	0.0073	CcSEcCtD
Norethindrone—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00161	0.00725	CcSEcCtD
Norethindrone—Renal failure—Sorafenib—thyroid cancer	0.0016	0.00723	CcSEcCtD
Norethindrone—Myocardial infarction—Sorafenib—thyroid cancer	0.0016	0.0072	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.0016	0.0072	CcSEcCtD
Norethindrone—Embolism—Doxorubicin—thyroid cancer	0.00155	0.007	CcSEcCtD
Norethindrone—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00154	0.00695	CcSEcCtD
Norethindrone—Oedema—Vandetanib—thyroid cancer	0.00154	0.00695	CcSEcCtD
Norethindrone—Thrombosis—Epirubicin—thyroid cancer	0.00152	0.00686	CcSEcCtD
Norethindrone—Skin disorder—Vandetanib—thyroid cancer	0.0015	0.00675	CcSEcCtD
Norethindrone—Haemoglobin—Sorafenib—thyroid cancer	0.00147	0.00663	CcSEcCtD
Norethindrone—Haemorrhage—Sorafenib—thyroid cancer	0.00146	0.0066	CcSEcCtD
Norethindrone—Dermatitis atopic—Epirubicin—thyroid cancer	0.00145	0.00656	CcSEcCtD
Norethindrone—Vaginal haemorrhage—Epirubicin—thyroid cancer	0.00145	0.00656	CcSEcCtD
Norethindrone—Connective tissue disorder—Sorafenib—thyroid cancer	0.00144	0.00648	CcSEcCtD
Norethindrone—Thrombosis—Doxorubicin—thyroid cancer	0.00141	0.00635	CcSEcCtD
Norethindrone—Insomnia—Vandetanib—thyroid cancer	0.00139	0.00629	CcSEcCtD
Norethindrone—Erythema multiforme—Sorafenib—thyroid cancer	0.00138	0.00624	CcSEcCtD
Norethindrone—Dyspepsia—Vandetanib—thyroid cancer	0.00136	0.00612	CcSEcCtD
Norethindrone—Vaginal haemorrhage—Doxorubicin—thyroid cancer	0.00135	0.00607	CcSEcCtD
Norethindrone—Dermatitis atopic—Doxorubicin—thyroid cancer	0.00135	0.00607	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00133	0.006	CcSEcCtD
Norethindrone—Fatigue—Vandetanib—thyroid cancer	0.00133	0.00599	CcSEcCtD
Norethindrone—Immune system disorder—Sorafenib—thyroid cancer	0.00132	0.00596	CcSEcCtD
Norethindrone—Alopecia—Sorafenib—thyroid cancer	0.00129	0.00583	CcSEcCtD
Norethindrone—Mental disorder—Sorafenib—thyroid cancer	0.00128	0.00578	CcSEcCtD
Norethindrone—Neoplasm malignant—Epirubicin—thyroid cancer	0.00126	0.00569	CcSEcCtD
Norethindrone—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00126	0.00568	CcSEcCtD
Norethindrone—Breast pain—Epirubicin—thyroid cancer	0.00123	0.00557	CcSEcCtD
Norethindrone—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00122	0.00553	CcSEcCtD
Norethindrone—Amenorrhoea—Epirubicin—thyroid cancer	0.00122	0.00553	CcSEcCtD
Norethindrone—Abdominal pain—Vandetanib—thyroid cancer	0.00122	0.00549	CcSEcCtD
Norethindrone—Neoplasm malignant—Doxorubicin—thyroid cancer	0.00117	0.00526	CcSEcCtD
Norethindrone—Breast pain—Doxorubicin—thyroid cancer	0.00114	0.00515	CcSEcCtD
Norethindrone—Amenorrhoea—Doxorubicin—thyroid cancer	0.00113	0.00511	CcSEcCtD
Norethindrone—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.00113	0.00511	CcSEcCtD
Norethindrone—Asthenia—Vandetanib—thyroid cancer	0.00111	0.00499	CcSEcCtD
Norethindrone—Pruritus—Vandetanib—thyroid cancer	0.00109	0.00492	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00108	0.00486	CcSEcCtD
Norethindrone—Pulmonary embolism—Epirubicin—thyroid cancer	0.00108	0.00486	CcSEcCtD
Norethindrone—Anaphylactic shock—Sorafenib—thyroid cancer	0.00104	0.00469	CcSEcCtD
Norethindrone—Dizziness—Vandetanib—thyroid cancer	0.00102	0.0046	CcSEcCtD
Norethindrone—Skin disorder—Sorafenib—thyroid cancer	0.00101	0.00455	CcSEcCtD
Norethindrone—Pulmonary embolism—Doxorubicin—thyroid cancer	0.000996	0.00449	CcSEcCtD
Norethindrone—Vomiting—Vandetanib—thyroid cancer	0.000979	0.00442	CcSEcCtD
Norethindrone—Rash—Vandetanib—thyroid cancer	0.000971	0.00438	CcSEcCtD
Norethindrone—Dermatitis—Vandetanib—thyroid cancer	0.00097	0.00438	CcSEcCtD
Norethindrone—Headache—Vandetanib—thyroid cancer	0.000965	0.00435	CcSEcCtD
Norethindrone—Nausea—Vandetanib—thyroid cancer	0.000915	0.00413	CcSEcCtD
Norethindrone—Dyspepsia—Sorafenib—thyroid cancer	0.000915	0.00413	CcSEcCtD
Norethindrone—Thrombophlebitis—Epirubicin—thyroid cancer	0.000902	0.00407	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000897	0.00405	CcSEcCtD
Norethindrone—Fatigue—Sorafenib—thyroid cancer	0.000896	0.00404	CcSEcCtD
Norethindrone—Photosensitivity—Epirubicin—thyroid cancer	0.00089	0.00401	CcSEcCtD
Norethindrone—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00085	0.00383	CcSEcCtD
Norethindrone—Thrombophlebitis—Doxorubicin—thyroid cancer	0.000835	0.00377	CcSEcCtD
Norethindrone—Urticaria—Sorafenib—thyroid cancer	0.000825	0.00372	CcSEcCtD
Norethindrone—Photosensitivity—Doxorubicin—thyroid cancer	0.000823	0.00371	CcSEcCtD
Norethindrone—Abdominal pain—Sorafenib—thyroid cancer	0.000821	0.00371	CcSEcCtD
Norethindrone—Renal impairment—Epirubicin—thyroid cancer	0.000821	0.0037	CcSEcCtD
Norethindrone—Purpura—Epirubicin—thyroid cancer	0.000811	0.00366	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000807	0.00364	CcSEcCtD
Norethindrone—Pain in extremity—Epirubicin—thyroid cancer	0.000781	0.00352	CcSEcCtD
Norethindrone—Affect lability—Epirubicin—thyroid cancer	0.000769	0.00347	CcSEcCtD
Norethindrone—Migraine—Epirubicin—thyroid cancer	0.000769	0.00347	CcSEcCtD
Norethindrone—Hypersensitivity—Sorafenib—thyroid cancer	0.000765	0.00345	CcSEcCtD
Norethindrone—Renal impairment—Doxorubicin—thyroid cancer	0.00076	0.00343	CcSEcCtD
Norethindrone—Purpura—Doxorubicin—thyroid cancer	0.00075	0.00338	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000747	0.00337	CcSEcCtD
Norethindrone—Asthenia—Sorafenib—thyroid cancer	0.000745	0.00336	CcSEcCtD
Norethindrone—Mood swings—Epirubicin—thyroid cancer	0.00074	0.00334	CcSEcCtD
Norethindrone—Pruritus—Sorafenib—thyroid cancer	0.000735	0.00332	CcSEcCtD
Norethindrone—Pain in extremity—Doxorubicin—thyroid cancer	0.000723	0.00326	CcSEcCtD
Norethindrone—Affect lability—Doxorubicin—thyroid cancer	0.000711	0.00321	CcSEcCtD
Norethindrone—Migraine—Doxorubicin—thyroid cancer	0.000711	0.00321	CcSEcCtD
Norethindrone—Breast disorder—Epirubicin—thyroid cancer	0.000706	0.00319	CcSEcCtD
Norethindrone—Dizziness—Sorafenib—thyroid cancer	0.000687	0.0031	CcSEcCtD
Norethindrone—Mood swings—Doxorubicin—thyroid cancer	0.000685	0.00309	CcSEcCtD
Norethindrone—Abdominal distension—Epirubicin—thyroid cancer	0.00068	0.00307	CcSEcCtD
Norethindrone—Vomiting—Sorafenib—thyroid cancer	0.000661	0.00298	CcSEcCtD
Norethindrone—Rash—Sorafenib—thyroid cancer	0.000655	0.00296	CcSEcCtD
Norethindrone—Dermatitis—Sorafenib—thyroid cancer	0.000654	0.00295	CcSEcCtD
Norethindrone—Breast disorder—Doxorubicin—thyroid cancer	0.000653	0.00295	CcSEcCtD
Norethindrone—Headache—Sorafenib—thyroid cancer	0.000651	0.00294	CcSEcCtD
Norethindrone—Abdominal distension—Doxorubicin—thyroid cancer	0.000629	0.00284	CcSEcCtD
Norethindrone—Nausea—Sorafenib—thyroid cancer	0.000617	0.00278	CcSEcCtD
Norethindrone—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000616	0.00278	CcSEcCtD
Norethindrone—Weight increased—Epirubicin—thyroid cancer	0.000614	0.00277	CcSEcCtD
Norethindrone—Drowsiness—Epirubicin—thyroid cancer	0.000602	0.00272	CcSEcCtD
Norethindrone—Renal failure—Epirubicin—thyroid cancer	0.000592	0.00267	CcSEcCtD
Norethindrone—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00057	0.00257	CcSEcCtD
Norethindrone—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000569	0.00257	CcSEcCtD
Norethindrone—Weight increased—Doxorubicin—thyroid cancer	0.000569	0.00257	CcSEcCtD
Norethindrone—Drowsiness—Doxorubicin—thyroid cancer	0.000557	0.00251	CcSEcCtD
Norethindrone—Renal failure—Doxorubicin—thyroid cancer	0.000548	0.00247	CcSEcCtD
Norethindrone—Haemoglobin—Epirubicin—thyroid cancer	0.000543	0.00245	CcSEcCtD
Norethindrone—Hepatitis—Epirubicin—thyroid cancer	0.00054	0.00244	CcSEcCtD
Norethindrone—Haemorrhage—Epirubicin—thyroid cancer	0.00054	0.00244	CcSEcCtD
Norethindrone—Connective tissue disorder—Epirubicin—thyroid cancer	0.000531	0.0024	CcSEcCtD
Norethindrone—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000527	0.00238	CcSEcCtD
Norethindrone—Erythema multiforme—Epirubicin—thyroid cancer	0.000511	0.00231	CcSEcCtD
Norethindrone—Haemoglobin—Doxorubicin—thyroid cancer	0.000503	0.00227	CcSEcCtD
Norethindrone—Haemorrhage—Doxorubicin—thyroid cancer	0.0005	0.00226	CcSEcCtD
Norethindrone—Hepatitis—Doxorubicin—thyroid cancer	0.0005	0.00226	CcSEcCtD
Norethindrone—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000491	0.00222	CcSEcCtD
Norethindrone—Immune system disorder—Epirubicin—thyroid cancer	0.000488	0.0022	CcSEcCtD
Norethindrone—Alopecia—Epirubicin—thyroid cancer	0.000478	0.00215	CcSEcCtD
Norethindrone—Mental disorder—Epirubicin—thyroid cancer	0.000473	0.00214	CcSEcCtD
Norethindrone—Erythema multiforme—Doxorubicin—thyroid cancer	0.000473	0.00213	CcSEcCtD
Norethindrone—Flatulence—Epirubicin—thyroid cancer	0.000464	0.00209	CcSEcCtD
Norethindrone—Tension—Epirubicin—thyroid cancer	0.000462	0.00208	CcSEcCtD
Norethindrone—Nervousness—Epirubicin—thyroid cancer	0.000457	0.00206	CcSEcCtD
Norethindrone—Immune system disorder—Doxorubicin—thyroid cancer	0.000452	0.00204	CcSEcCtD
Norethindrone—Alopecia—Doxorubicin—thyroid cancer	0.000442	0.00199	CcSEcCtD
Norethindrone—Mental disorder—Doxorubicin—thyroid cancer	0.000438	0.00198	CcSEcCtD
Norethindrone—Flatulence—Doxorubicin—thyroid cancer	0.000429	0.00194	CcSEcCtD
Norethindrone—Tension—Doxorubicin—thyroid cancer	0.000427	0.00193	CcSEcCtD
Norethindrone—Nervousness—Doxorubicin—thyroid cancer	0.000423	0.00191	CcSEcCtD
Norethindrone—Convulsion—Epirubicin—thyroid cancer	0.000408	0.00184	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000398	0.00179	CcSEcCtD
Norethindrone—Oedema—Epirubicin—thyroid cancer	0.000384	0.00173	CcSEcCtD
Norethindrone—Anaphylactic shock—Epirubicin—thyroid cancer	0.000384	0.00173	CcSEcCtD
Norethindrone—Convulsion—Doxorubicin—thyroid cancer	0.000377	0.0017	CcSEcCtD
Norethindrone—Skin disorder—Epirubicin—thyroid cancer	0.000373	0.00168	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000368	0.00166	CcSEcCtD
Norethindrone—Oedema—Doxorubicin—thyroid cancer	0.000355	0.0016	CcSEcCtD
Norethindrone—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000355	0.0016	CcSEcCtD
Norethindrone—Insomnia—Epirubicin—thyroid cancer	0.000347	0.00157	CcSEcCtD
Norethindrone—Skin disorder—Doxorubicin—thyroid cancer	0.000345	0.00156	CcSEcCtD
Norethindrone—Somnolence—Epirubicin—thyroid cancer	0.000341	0.00154	CcSEcCtD
Norethindrone—Dyspepsia—Epirubicin—thyroid cancer	0.000338	0.00152	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000331	0.0015	CcSEcCtD
Norethindrone—Fatigue—Epirubicin—thyroid cancer	0.000331	0.00149	CcSEcCtD
Norethindrone—Insomnia—Doxorubicin—thyroid cancer	0.000321	0.00145	CcSEcCtD
Norethindrone—Somnolence—Doxorubicin—thyroid cancer	0.000316	0.00143	CcSEcCtD
Norethindrone—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000314	0.00142	CcSEcCtD
Norethindrone—Dyspepsia—Doxorubicin—thyroid cancer	0.000313	0.00141	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000307	0.00138	CcSEcCtD
Norethindrone—Fatigue—Doxorubicin—thyroid cancer	0.000306	0.00138	CcSEcCtD
Norethindrone—Urticaria—Epirubicin—thyroid cancer	0.000305	0.00138	CcSEcCtD
Norethindrone—Abdominal pain—Epirubicin—thyroid cancer	0.000304	0.00137	CcSEcCtD
Norethindrone—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000291	0.00131	CcSEcCtD
Norethindrone—Hypersensitivity—Epirubicin—thyroid cancer	0.000283	0.00128	CcSEcCtD
Norethindrone—Urticaria—Doxorubicin—thyroid cancer	0.000282	0.00127	CcSEcCtD
Norethindrone—Abdominal pain—Doxorubicin—thyroid cancer	0.000281	0.00127	CcSEcCtD
Norethindrone—Asthenia—Epirubicin—thyroid cancer	0.000275	0.00124	CcSEcCtD
Norethindrone—Pruritus—Epirubicin—thyroid cancer	0.000272	0.00123	CcSEcCtD
Norethindrone—Hypersensitivity—Doxorubicin—thyroid cancer	0.000262	0.00118	CcSEcCtD
Norethindrone—Asthenia—Doxorubicin—thyroid cancer	0.000255	0.00115	CcSEcCtD
Norethindrone—Dizziness—Epirubicin—thyroid cancer	0.000254	0.00115	CcSEcCtD
Norethindrone—Pruritus—Doxorubicin—thyroid cancer	0.000251	0.00113	CcSEcCtD
Norethindrone—Vomiting—Epirubicin—thyroid cancer	0.000244	0.0011	CcSEcCtD
Norethindrone—Rash—Epirubicin—thyroid cancer	0.000242	0.00109	CcSEcCtD
Norethindrone—Dermatitis—Epirubicin—thyroid cancer	0.000242	0.00109	CcSEcCtD
Norethindrone—Headache—Epirubicin—thyroid cancer	0.000241	0.00109	CcSEcCtD
Norethindrone—Dizziness—Doxorubicin—thyroid cancer	0.000235	0.00106	CcSEcCtD
Norethindrone—Nausea—Epirubicin—thyroid cancer	0.000228	0.00103	CcSEcCtD
Norethindrone—Vomiting—Doxorubicin—thyroid cancer	0.000226	0.00102	CcSEcCtD
Norethindrone—Rash—Doxorubicin—thyroid cancer	0.000224	0.00101	CcSEcCtD
Norethindrone—Dermatitis—Doxorubicin—thyroid cancer	0.000224	0.00101	CcSEcCtD
Norethindrone—Headache—Doxorubicin—thyroid cancer	0.000223	0.001	CcSEcCtD
Norethindrone—Nausea—Doxorubicin—thyroid cancer	0.000211	0.000952	CcSEcCtD
